Navigation Links
Boehringer Ingelheim Pharmaceuticals, Inc. Receives the NCQA 'Seal Of Approval'
Date:2/19/2008

RIDGEFIELD, Conn., Feb. 19 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that it has received the prestigious certification from the National Committee for Quality Assurance (NCQA) for its educational resources and programs related to chronic obstructive pulmonary disease (COPD). A chronic illness that may result in severe morbidity, COPD, which includes chronic bronchitis, emphysema, or both, is the fourth-leading cause of death in the United States. (1)

To address this problem and inform the public about COPD, Boehringer Ingelheim has and continues to raise awareness about this serious disease through education and initiatives for patients, healthcare practitioners, and health plans. As a result of these efforts, the company has become one of just a few recognized by the NCQA for their efforts.

"This recognition is an important milestone that highlights our commitment to making a difference in the management of chronic diseases," said Chris Barrett, Senior Vice President, Managed Markets. "Boehringer Ingelheim is dedicated to helping to improve the lives of people living with serious chronic diseases such as COPD, and we continue to collaborate with the NCQA as we develop health management programs in other important areas, such as stroke and prevention of secondary stroke."

Margaret E. O'Kane, President of NCQA agrees. "Earning NCQA Disease Management Certification indicates that a disease management (DM) program excels in the specific area in which it was reviewed, either program design, patient outreach, or DM systems. It's an accomplishment of which to be very proud."

About Boehringer Ingelheim

Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies. The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 137 affiliates in 47 countries and approximately 38,400 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
For more information, please visit http://us.boehringer-ingelheim.com.

(1.) National Heart, Lung, and Blood Institute. Morbidity & Mortality:

2007 chart book on cardiovascular, lung, and blood diseases.

[NHLBI2007/P9/Chart 2-8] June 2007. U.S. Department of Health and

Human Services, National Institutes of Health; 2007.

http://www.nhlbi.nih.gov/resources/docs/cht-book.htm. Accessed December 12,

2007.


'/>"/>
SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Boehringer Ingelheim Receives Top Honor as Worlds Most Respected Biopharmaceutical Employer in Science 2007 Top Employers Survey
2. Dalton Medicinal Chemistry Partners Achieves Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
3. Astellas and Boehringer Ingelheim Reach Settlement Agreement with Ranbaxy on Flomax Patent Case
4. Dalton Medicinal Chemistry Partners Achieves Another Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
5. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
6. Prestwick Pharmaceuticals, Inc. Continues to Build Management Team With Appointment of Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer
7. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
8. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
9. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
10. NPS Pharmaceuticals, Inc. Announces an Increase in Tender Offer Price for Its 3.0% Convertible Notes Due 2008 and Extends Expiration Date Until October 17, 2007
11. Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... Singh ... orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of ... SBT-100 is able to cross the cell membrane and bind intracellular STAT3 and ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and CEO of ... Club. The event entitled “Stem Cells and Their Regenerative Powers,” was ... Dr. Harman, DVM, MPVM was joined by two human doctors: Peter B. Hanson, M.D., ...
(Date:10/10/2017)... ... 2017 , ... The Pittcon Program Committee is pleased to ... who have made outstanding contributions to analytical chemistry and applied spectroscopy. Each award ... conference and exposition for laboratory science, which will be held February 26-March 1, ...
(Date:10/9/2017)... ... 2017 , ... The Giving Tree Wellness Center announces the ... of consumers who are incorporating medical marijuana into their wellness and health regimens. ... operators of two successful Valley dispensaries, The Giving Tree’s two founders, Lilach Mazor ...
Breaking Biology Technology:
(Date:5/23/2017)... robotic gym for the rehabilitation and functional motor sense evaluation of lower ... . The first 30 robots will be available from June in ... The technology was developed and patented at the IIT laboratories and has ... to a 10 million euro investment from entrepreneur Sergio Dompè. ... ...
(Date:5/16/2017)... May 16, 2017   Bridge Patient Portal ... and MD EMR Systems , an electronic ... for GE, have established a partnership to build ... and the GE Centricity™ products, including Centricity Practice ... These new integrations will allow healthcare ...
(Date:4/24/2017)... Janice Kephart , former 9/11 ... Partners, LLP (IdSP) , today issues the following ... March 6, 2017 Executive Order: Protecting the ... be instilled with greater confidence, enabling the reactivation ... applications are suspended by until at least July ...
Breaking Biology News(10 mins):